Poteligeo Market Report 2026

Poteligeo Market Overview

• The Poteligeo market growth in the historic period has been driven by increasing incidence of rare t-cell lymphomas, regulatory approvals for targeted biologics • Market expansion is supported by rising demand for precision oncology drugs, increasing adoption of biologics in hematologic cancers • Growth Driver: Rising Prevalence Of Lymphoma To Drive The Growth Of The Market • Market Trend: Adoption of Real World Evidence Programs to Support Poteligeo in Cutaneous T Cell Lymphoma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Poteligeo Market?

Poteligeo is a monoclonal antibody used to treat certain cancers, specifically cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). It works by targeting and inhibiting the CCR4 receptor found on the surface of cancerous T-cells in these cancers. By binding to CCR4, it helps reduce the proliferation of these malignant cells and may lead to their destruction. The main types of indications for poteligeo are mycosis fungoides, sezary syndrome, and peripheral t-cell lymphoma (PTCL). Mycosis fungoides is a rare type of cutaneous T-cell lymphoma characterized by abnormal T-cell growth in the skin, causing lesions. It is distributed through various channels such as direct sales by pharmaceutical companies, wholesale distributors, and retail pharmacies, and is used by various end users including hospitals, oncology clinics, and home healthcare providers.

What Is The Poteligeo Market Growth Forecast?

The growth in the forecast period can be attributed to rising demand for precision oncology drugs, increasing adoption of biologics in hematologic cancers, expansion of personalized medicine approaches, growing investments in advanced biologic manufacturing, increasing focus on rare cancer treatment pipelines. Major trends in the forecast period include increasing adoption of targeted immunotherapy treatments, rising focus on ccr4-targeted oncology therapies, expansion of monoclonal antibody manufacturing capabilities, growing emphasis on personalized cancer treatment protocols, enhanced clinical monitoring of rare t-cell malignancies.

Global Poteligeo Market Segmentation

1) By Indication: Mycosis Fungoides, Sezary Syndrome, Peripheral T-cell Lymphoma (PTCL) 2) By Distribution Channel: Direct Sales By Pharmaceutical Companies, Wholesale Distributors, Retail Pharmacies 3) By End User: Hospitals, Oncology Clinics, Home Healthcare Providers

What Is The Driver Of The Poteligeo Market?

The rising prevalence of lymphoma is anticipated to propel the growth of the poteligeo market going forward. Lymphoma refers to a type of cancer that originates in the lymphatic system, which is a part of the body's immune system and primarily affects the lymph nodes, spleen, and bone marrow. The rising cases of lymphoma are attributed to factors such as an aging population, increased exposure to environmental risk factors, and advancements in diagnostic technologies. Poteligeo (mogamulizumab) aids in the treatment of lymphoma by targeting and inhibiting the CCR4 receptor on cancerous T-cells, thereby reducing tumor growth and improving the immune system's response against the cancer cells. For instance, in 2023, according to the American Cancer Society, a US-based non-profit organization, the estimated number of new lymphoma cancer cases increased from 89,010 in 2022 to 89,380 in 2023. Therefore, the rising prevalence of lymphoma is driving the growth of the poteligeo industry.

Key Players In The Global Poteligeo Market

Major companies operating in the poteligeo market are Kyowa Kirin Co. Ltd.

Global Poteligeo Market Trends and Insights

Major companies are operating in the poteligeo market, focusing on developing technological advancements such as CCR4-targeted monoclonal antibody therapies for more precise treatment of cutaneous T-cell lymphoma, improving efficacy and minimizing off-target effects compared to traditional chemotherapy. A CCR4-targeted monoclonal antibody binds to the CC chemokine receptor 4 on malignant T-cells, triggering antibody-dependent cellular cytotoxicity (ADCC) to selectively destroy cancer cells while sparing healthy tissue. For instance, in September 2023, Kyowa Kirin International, a Japan-based specialty pharmaceutical company, demonstrated real-world evidence for POTELIGEO (mogamulizumab) at the EORTC CLTG meeting. The program included multiple international registries, showing consistent safety and effectiveness in routine clinical practice beyond controlled trials, supporting broader adoption and clinical confidence in CCR4-positive cutaneous T-cell lymphoma treatment.

What Are Latest Mergers And Acquisitions In The Poteligeo Market?

In January 2025, Kyowa Kirin, a Japan-based specialty pharmaceutical company, partnered with Swixx BioPharma to expand access to POTELIGEO (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe, including Croatia and Bulgaria. Through this collaboration, the companies aim to improve patient access, facilitate reimbursement, and strengthen local commercial support for POTELIGEO. This partnership highlights the Poteligeo market’s growing focus on regional expansion and improving availability of CCR4-targeting therapies. Swixx BioPharma, a Switzerland-based provider of pharmaceutical distribution and commercialization services.

Regional Insights

North America was the largest region in the poteligeo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Poteligeo Market?

The poteligeo market consists of sales of mogamulizumab injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Poteligeo Market Report 2026?

The poteligeo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the poteligeo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.